Loading
Life sciences · Journal article
Frontiers in Cell and Developmental Biology · October 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Immune checkpoint blockade targeting PD-1/PD-L1 has reshaped cancer therapy across multiple tumor types. However, primary and acquired resistance remain major barriers to durable clinical benefit. Increasing evidence indicates that immunotherapy resistance is not driven by isolated molecular alterations, but by coordinated changes involving tumor-intrinsic immune escape, immunosuppressive tumor microenvironments, systemic inflammatory remodeling, and adaptive biomarker evolution under therapeutic pressure. This review focuses on pan-cancer biomarkers of immune therapy resistance from the perspective of mechanisms and clinical translation. First, we summarize targetable biomarker classes that link resistance biology to therapeutic sensitization across cancers, including transcription factors, genomic alterations, immune checkpoint proteins and metabolic regulators. For each class, we highlight representative cancer types in which experimental or clinical evidence supports their role in immunotherapy resistance. Second, we discuss the mechanistic basis of resistance-associated biomarkers, emphasizing antigen presentation defects, impaired interferon signaling, oncogenic pathway activation, T-cell exhaustion, myeloid and stromal immunosuppression, metabolic reprogramming, and dynamic systemic immune remodeling. These mechanisms provide a biological perspective for interpreting biomarkers not only as predictors of treatment response, but also as functional indicators of resistance evolution. By integrating biomarker classification, resistance mechanisms, and therapeutic sensitization strategies, this review aims to provide a new perspective for using pan-cancer resistance biomarkers to guide rational combination immunotherapy and improve precision cancer treatment.